135 related articles for article (PubMed ID: 23486270)
21. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
22. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.
Takeda M; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 May; 8(5):654-7. PubMed ID: 23584297
[TBL] [Abstract][Full Text] [Related]
23. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
24. Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case.
Kaseda K; Watanabe K; Asakura K; Kazama A
World J Surg Oncol; 2015 Feb; 13():74. PubMed ID: 25889062
[TBL] [Abstract][Full Text] [Related]
25. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
Cao Y; Xiao G; Qiu X; Ye S; Lin T
PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
[TBL] [Abstract][Full Text] [Related]
27. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.
Omachi N; Shimizu S; Kawaguchi T; Tezuka K; Kanazu M; Tamiya A; Asami K; Okishio K; Kitaichi M; Atagi S
J Thorac Oncol; 2014 Jun; 9(6):e40-2. PubMed ID: 24828670
[No Abstract] [Full Text] [Related]
28. Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib.
Jao K; Tomasini P; Labbe C; Doherty M; Shepherd FA
J Thorac Oncol; 2015 Jun; 10(6):965-6. PubMed ID: 26001146
[No Abstract] [Full Text] [Related]
29. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
[No Abstract] [Full Text] [Related]
30. Prospective screening for ALK: clinical features and outcome according to ALK status.
Fallet V; Cadranel J; Doubre H; Toper C; Monnet I; Chinet T; Oliviero G; Foulon G; De Cremoux H; Vieira T; Antoine M; Wislez M
Eur J Cancer; 2014 May; 50(7):1239-46. PubMed ID: 24589437
[TBL] [Abstract][Full Text] [Related]
31. Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene.
Kimura M; Endo H; Inoue T; Nishino K; Uchida J; Kumagai T; Kukita Y; Kato K; Imamura F; Inoue M
J Thorac Oncol; 2015 Mar; 10(3):527-30. PubMed ID: 25695223
[TBL] [Abstract][Full Text] [Related]
32. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
33. Clinical response to crizotinib retreatment after acquisition of drug resistance.
Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
[No Abstract] [Full Text] [Related]
34. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
[No Abstract] [Full Text] [Related]
35. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
36. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
[No Abstract] [Full Text] [Related]
37. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
Mirshahidi HR; Mirshahidi S
Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
[TBL] [Abstract][Full Text] [Related]
40. Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.
Pop O; Pirvu A; Toffart AC; Moro-Sibilot D
J Thorac Oncol; 2012 Aug; 7(8):e1-2. PubMed ID: 22797152
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
